<DOC>
	<DOCNO>NCT02476617</DOCNO>
	<brief_summary>A study evaluate immune restoration follow removal viral antigen non-cirrhotic HCV GT1a treatment-naïve pegylated-interferon ( pegIFN ) /RBV treatment-experienced adult receive treatment ombitasvir/ABT-450/ritonavir dasabuvir coadministered RBV 12 week .</brief_summary>
	<brief_title>Ombitasvir/ABT-450/Ritonavir ( Ombitasvir/ABT-450/r ) With Dasabuvir Ribavirin ( RBV ) Treatment Naive Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults</brief_title>
	<detailed_description>A study evaluate role ombitasvir/ABT-450/ritonavir dasabuvir coadministered RBV treatment lead sustain virologic response 12 week post-dosing ( SVR12 ) change baseline IFN-stimulated gene ( ISG ) expression peripheral blood mononucleated cell ( PBMCs ) HCV GT1a-infected adult subject .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>1 . Screening laboratory result indicate HCV GT1a infection . 2 . Chronic HCV infection . 3 . Subjects must noncirrhotic . 4 . Subjects must treatmentnaïve documentation adherent prior pegIFN/RBV combination therapy meet criterion prior pegIFN/RBV treatment failure . 5 . Subjects must meet specific human leukocyte antigen ( HLA ) allele requirement . 1 . Women pregnant breastfeeding . 2 . Positive test result hepatitis B surface antigen ( HBsAg ) antihuman immunodeficiency virus antibody ( HIV Ab ) positive immunoassay . 3 . Clinically significant abnormality comorbidities , HCV infection , make subject unsuitable study treatment . 4 . Current enrollment another interventional clinical study , previous enrollment study , prior current use investigational commercially available antiHCV agent pegIFN RBV ( include previous exposure ABT450 , ombitasvir , dasabuvir ) , receipt investigational product within 6 week prior study drug administration . 5 . History solid organ transplant . 6 . Screening laboratory analysis show abnormal result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Treatment naive</keyword>
	<keyword>Interferon free</keyword>
	<keyword>HCV</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Hepatitis C Genotype 1a</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>pegIFN/RBV experience</keyword>
</DOC>